Assessing the potential clinical utility of transplantations of neural and mesenchymal stem cells for treating neurodegenerative diseases.
Assessing the potential clinical utility of transplantations of neural and mesenchymal stem cells for treating neurodegenerative diseases.
复制标题
DOI：
10.1007/978-1-61779-815-3_10
复制
发表时间：
2012-01-01
期刊：
影响因子：
--
通讯作者：
Dunbar, G L
中科院分区：
文献类型：
--
作者：
Lescaudron, Laurent;Boyer, C;Dunbar, G L
神经退行性疾病的治疗对患者的长期健康影响不大。然而，神经退行性疾病动物模型和患者中来源于流产胚胎脑组织的神经母细胞的细胞移植已经证明在大脑中存活和功能。然而，由于使用这种胎儿组织而引起的伦理和功能问题使大多数临床试验停止。因此，需要新的细胞来源，科学家们将重点放在神经（NSCs）和间充质干细胞（MSCs）上。当移植到患有帕金森病或亨廷顿病的动物大脑中时，NSCs和MSCs能够通过促进神经保护和免疫调节来诱导部分功能恢复。由于骨髓等来源，MSCs比NSCs更容易获得。然而，MSCs不能在NSCs所在的体内分化为神经元。因此，NSCs和MSCs的移植是脑再生医学研究的热点。在本章中，我们详细介绍了NSCs和MSCs的分离方法以及用于治疗啮齿动物神经退行性损伤模型的移植程序。
Treatments for neurodegenerative diseases have little impact on the long-term patient health. However, cellular transplants of neuroblasts derived from the aborted embryonic brain tissue in animal models of neurodegenerative disorders and in patients have demonstrated survival and functionality in the brain. However, ethical and functional problems due to the use of this fetal tissue stopped most of the clinical trials. Therefore, new cell sources were needed, and scientists focused on neural (NSCs) and mesenchymal stem cells (MSCs). When transplanted in the brain of animals with Parkinson's or Huntington's disease, NSCs and MSCs were able to induce partial functional recovery by promoting neuroprotection and immunomodulation. MSCs are more readily accessible than NSCs due to sources such as the bone marrow. However, MSCs are not capable of differentiating into neurons in vivo where NSCs are. Thus, transplantation of NSCs and MSCs is interesting for brain regenerative medicine. In this chapter, we detail the methods for NSCs and MSCs isolation as well as the transplantation procedures used to treat rodent models of neurodegenerative damage.